| __timestamp | Bristol-Myers Squibb Company | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 16758000 |
| Thursday, January 1, 2015 | 5001000000 | 17793000 |
| Friday, January 1, 2016 | 5002000000 | 18761000 |
| Sunday, January 1, 2017 | 4849000000 | 19287000 |
| Monday, January 1, 2018 | 4551000000 | 18707000 |
| Tuesday, January 1, 2019 | 4871000000 | 20893000 |
| Wednesday, January 1, 2020 | 7661000000 | 25678000 |
| Friday, January 1, 2021 | 7690000000 | 29665000 |
| Saturday, January 1, 2022 | 7814000000 | 43628000 |
| Sunday, January 1, 2023 | 7772000000 | 69135000 |
| Monday, January 1, 2024 | 8414000000 |
Data in motion
In the ever-evolving pharmaceutical landscape, operational efficiency is key. Over the past decade, Bristol-Myers Squibb Company (BMS) and Geron Corporation have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. BMS, a giant in the industry, has consistently maintained SG&A expenses averaging around $6 billion annually, peaking in 2022 with a 38% increase from 2018. This reflects their expansive operations and robust market presence. In contrast, Geron Corporation, a smaller player, has seen its SG&A expenses grow by over 300% from 2014 to 2023, indicating a strategic push towards growth and development. This comparison highlights the diverse approaches within the industry, where scale and strategy dictate financial priorities. As the pharmaceutical sector continues to innovate, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Bristol-Myers Squibb Company or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Bristol-Myers Squibb Company or Dr. Reddy's Laboratories Limited: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for MorphoSys AG and Geron Corporation